Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Drug Firms Fear PBM ‘Discrimination’ Over List Price Reductions, Azar Tells Hearing

Executive Summary

HHS Secretary Azar explains why companies have not voluntarily lowered prices as yet, despite President Trump’s recent comments. He also discussed using regulations to prohibit rebates.


Related Content

PBMs’ Impact On Drug Prices Probed By House Committee Leaders
US Senators Seek 'Clarity’ On Middlemen Obstructing List Price Reductions
Shifting Medicare Part B Drugs To Part D: Legislative Prospects Cloudy
The Trump Effect On Drug Pricing: Uncertainty Is The Only Constant
Trump's Drug Pricing Blueprint: An Administrative Vs. Legislative Breakdown
Lowering Insulin Costs: Sanofi Seeks HHS Support For Expanding Assistance To Medicare Patients
Trump Expecting Rx Price Reduction Announcements In Two Weeks
A World Without Rebates: Is FDA’s Gottlieb Offering New Vision?





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts